Proficio Capital Partners LLC Takes Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Proficio Capital Partners LLC bought a new position in Privia Health Group, Inc. (NASDAQ:PRVA) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 23,714 shares of the company’s stock, valued at approximately $464,000.

Other hedge funds have also modified their holdings of the company. Intech Investment Management LLC purchased a new position in Privia Health Group during the third quarter worth approximately $462,000. Charles Schwab Investment Management Inc. raised its position in shares of Privia Health Group by 6.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,064,224 shares of the company’s stock worth $19,380,000 after buying an additional 65,152 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Privia Health Group in the third quarter valued at $1,206,000. FMR LLC boosted its holdings in Privia Health Group by 1.5% in the third quarter. FMR LLC now owns 18,169,043 shares of the company’s stock valued at $330,858,000 after acquiring an additional 271,645 shares during the last quarter. Finally, Quantbot Technologies LP grew its position in Privia Health Group by 82.6% during the third quarter. Quantbot Technologies LP now owns 37,375 shares of the company’s stock valued at $681,000 after acquiring an additional 16,904 shares during the period. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Stock Up 2.5 %

Shares of NASDAQ PRVA opened at $23.92 on Tuesday. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.04. The business has a 50 day moving average price of $23.71 and a two-hundred day moving average price of $21.08. The firm has a market cap of $2.88 billion, a PE ratio of 239.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.85.

Analysts Set New Price Targets

Several research analysts recently commented on PRVA shares. Canaccord Genuity Group raised their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $26.00 target price on shares of Privia Health Group in a research note on Thursday, January 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Privia Health Group in a research report on Friday. JMP Securities set a $29.00 price objective on Privia Health Group in a research report on Friday, February 28th. Finally, Macquarie assumed coverage on Privia Health Group in a research note on Monday, December 16th. They set an “outperform” rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $26.67.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.